Skip to content
← Full study record

NCT02224781 · OUTCOME

Overall Health

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma · Source last updated 2026-08-28

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
assessed at baseline and 2 years after initiation of treatment

What was measured

The quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) score was used to measure overall health. Differences between treatment groups in the mean Q-TWiST score were calculated. For each score, a 95% confidence interval (CI) and two-sided P-value for testing the null hypothesis of no difference between treatment groups were conducted using a Z-test (with normal approximation), with standard errors calculated by the bootstrap method.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
The quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) score was used to measure overall health. Differences between treatment groups in the mean Q-TWiST score were calculated. For each score, a 95% confidence interval (CI) and two-sided P-value for testing the null hypothesis of no difference between treatment groups were conducted using a Z-test (with normal approximation), with standard errors calculated by the bootstrap method.
reporting Status
NOT_POSTED
time Frame
assessed at baseline and 2 years after initiation of treatment
title
Overall Health
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice